Melbourne, Australia; 27 September 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering aspects of Cynata’s proprietary Cymerus™ mesenchymal stem cell technology.
The patent entitled “A method of making primate cells expressing apelin receptor that have mesangioblast potential” covers certain proprietary methods relating to the platform’s ability to efficiently manufacture mesenchymal stem cells at scale. The patent is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.
“We are delighted that the USPTO has granted this patent, building further strength in Cynata’s comprehensive patent portfolio”, said Dr Ross Macdonald, Cynata’s Chief Executive Officer. “Our proprietary Cymerus stem cell manufacturing technology enables the scalable manufacture of consistent, high-quality mesenchymal stem cell therapeutic products targeting a range of devastating diseases worldwide.”
The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and shareholders of Cynata.
The patent has an expiration date of 1 February 2028.
CONTACTS
Dr Ross Macdonald, CEO, 0412 119343, [email protected]cynata.com
Daniel Paproth, Australia Media Contact, 0421 858 982 , [email protected]
Laura Bagby, U.S. Media Contact, 312-448-8098, [email protected]
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.
